Rippon Ubhi 

Sanofi’s Rippon Ubhi appointed new Chair of European Medicines Group

Sanofi has announced that Rippon Ubhi has been appointed as the new Chair of the European Medicines Group (EMG). She will continue her role as Country Lead for Sanofi UK & Ireland alongside this new appointment.

Rippon has extensive experience of shaping healthcare systems to support better patient access to innovative medicines.

She brings close to 20 years of senior commercial leadership experience in global, international (emerging markets including China) and affiliate organisations including having lived and worked in Japan, United States and the UK over the past decade, working across pre-launch, launch and established business & culture environments.

She joined Sanofi in late 2022 after 18 years at AstraZeneca and has since played a pivotal role in leading the UK & Ireland business to success.

The European Medicines Group (EMG) represents 22 continental European headquartered research-based pharmaceutical companies, which together are significant investors and employers in the UK and make a major contribution to the NHS and its ability to deliver better patient outcomes across a broad range of conditions.

The EMG works closely with the industry’s trade body, the Association of the British Pharmaceutical Industry and works with the UK Government, the NHS and wider stakeholders for the benefit of patients.

Rippon said: “I am honoured to take on the role of Chair of the European Medicines Group at such an exciting time for our industry. This is a great opportunity to contribute to shaping the future of healthcare in the UK and to work towards our shared goal of improving patients’ lives.”